In-depth briefings on agency actions, clinical and preclinical research, and state and federal law and policy — with primary sources, scores, and clear limits on claims.
A longitudinal biomarker preprint links metabolic burden to esketamine response in treatment-resistant depression, offering early clues for personalized therapy. Findings are preliminary and require validation.
Sep 07, 2026
Clinical TrialsThe Bio-K/NNDC multicenter trial mapped metabolomic changes after IV ketamine in adults with treatment-resistant depression, showing broad metabolic effects and partial remission, but no clear metabolomic predictors of response.
Sep 06, 2026
Clinical TrialsThe Bio-K/NNDC multicenter trial offers the most detailed metabolomic profile of IV racemic ketamine in treatment-resistant depression to date, revealing broad metabolic changes but no predictive biomarkers for antidepressant response.
Sep 06, 2026
Clinical TrialsA new review synthesizes evidence on psilocybin’s potential as an anxiolytic, detailing neurobiological mechanisms, clinical trial data, and unresolved questions shaping research and regulatory priorities.
Sep 05, 2026
Clinical TrialsPhase 2 clinical trials of satoprodil, a GluN2B-selective NMDA modulator, showed no significant efficacy over placebo in major depressive disorder. These results challenge the glutamatergic hypothesis and may shift research and investment strategies.
Sep 05, 2026
MarketRecent investments by high-profile tech figures in U.S. psychedelics signal a shift toward mainstream acceptance and rapid industry growth, but also introduce potential regulatory and ethical complexities.
Sep 05, 2026
PolicyNew Zealand has authorized a psychiatrist to prescribe MDMA, transitioning the drug from research to clinical use. This development presents new opportunities and challenges for clinicians, regulators, and the emerging psychedelic industry.
Sep 05, 2026
PolicyMDMA is now federally prescribable for severe PTSD in the US, following FDA approval. This policy shift enables regulated psychedelic therapy, prompts new research, and raises questions on safety, access, and payer coverage.
Sep 05, 2026
PolicyA newly published national survey of Irish stakeholders offers early data on attitudes toward psychedelic-assisted therapy, revealing both enthusiasm and significant barriers. These findings may shape future policy, research, and clinical adoption in Ireland.
Sep 04, 2026
NeuroscienceA new preclinical study shows that defective synapto-nuclear signaling underlies motoneuron vulnerability in ALS and that enhancing cAMP/PKA signaling can restore function in a mouse model, offering insights for future neuroplasticity research.
Sep 04, 2026
Clinical TrialsA 2026 controlled EEG study finds that psilocybin’s long-term positive effects may be predicted by sub-acute brain activity changes, not just acute experiences. This insight could reshape clinical trial endpoints and patient selection in psychedelic research.
Sep 04, 2026
PolicyNew Zealand now permits psychiatrists to prescribe MDMA for severe PTSD, making it a global pioneer in clinical psychedelic policy. This decision is expected to influence research, regulatory, and clinical landscapes internationally.
Sep 04, 2026
PolicyThe FDA’s 2026 approval of MDMA as a PTSD treatment represents a pivotal regulatory and clinical milestone, transforming patient access, insurance coverage, and the trajectory of psychedelic medicine in the United States.
Sep 04, 2026
Clinical TrialsA major 2026 review details the complexity of geriatric mental disorders, notes interest in ketamine, and calls out the lack of older adult inclusion in psychiatric and psychedelic trials—an urgent challenge for research and policy.
Sep 04, 2026
Clinical TrialsA pilot trial of MDMA-assisted couples therapy for U.S. veterans with PTSD showed large reductions in symptoms and improved relationship functioning, with no serious safety events. Findings support further research in dyadic psychedelic-assisted therapies.
Sep 04, 2026
PolicyA landmark federal report advises U.S. states to ready their laws and infrastructure for FDA approval of psychedelic therapies, signaling a shift in national policy and highlighting trial design issues such as the blinding problem.
Sep 04, 2026
PolicyNew Zealand’s 2026 approval of MDMA for PTSD treatment marks a global first in clinical psychedelic policy, expanding patient access and setting a precedent for international regulatory harmonization. Key risks, research gaps, and operational challenges remain.
Sep 04, 2026
Clinical TrialsThe Department of Veterans Affairs has launched a psilocybin-assisted therapy trial in Alabama, expanding access to psychedelic research for veterans in conservative regions and signaling a shift in federal engagement with novel mental health treatments.
Sep 04, 2026
Clinical TrialsMD Anderson Cancer Center will conduct a clinical trial testing psilocybin for the prevention of chemotherapy-induced neurotoxicity. This marks a significant step in mainstreaming psychedelic research for non-psychiatric indications and could reshape regulatory and clinical perspectives.
Sep 04, 2026
PolicyNew Zealand’s regulatory approval of MDMA for severe PTSD marks a pivotal shift in psychedelic therapy policy, with implications for clinical practice, research, and international regulatory trends. This briefing examines the decision’s context, mechanisms, and potential impact.
Sep 04, 2026
Public HealthA 2026 study using forensic lab analysis in emergency departments offers objective data on illicit and novel psychoactive drug exposures, improving clinical protocols and informing early warning systems for public health and harm reduction.
Sep 03, 2026
Clinical TrialsA 2026 PubMed study details how ketamine's effects on breathing and cortical function depend on dose in ambulatory anesthesia. These findings may reshape protocols, risk assessment, and regulatory oversight for ketamine use in clinical and off-label settings.
Sep 03, 2026
NeuroscienceA new ENIGMA PTSD Consortium preprint analyzes amygdala-hippocampus connectivity across sites, advancing understanding of PTSD neural circuits and informing future psychedelic research and biomarker development.
Sep 03, 2026
NeuroscienceA 2026 preclinical study finds that the brain’s response to anxiety shifts from serotonergic to dopaminergic pathways depending on stress intensity, challenging assumptions about uniform treatment response and guiding future clinical trial design.
Sep 03, 2026
Clinical TrialsA recent case report describes successful ketamine use for severe opioid withdrawal triggered by buprenorphine. While not peer-reviewed or generalizable, this finding may spark controlled trials on ketamine’s role in acute withdrawal management.
Sep 03, 2026
Clinical TrialsA 2026 review synthesizes multi-omics approaches—pharmacogenomics, metabolomics, and more—in guiding treatment-resistant depression. While discovery signals are promising, most omics-guided strategies remain investigational and lack clinical utility, shaping future psychedelic research but not current practice.
Sep 03, 2026
Clinical TrialsThis analysis reviews 2026 best-practice guidance for short-term ketamine use in depression, highlighting regulatory distinctions, clinical protocols, and key evidence gaps for oral, subcutaneous, and nasal formulations.
Sep 03, 2026
PolicyOregon’s legal psilocybin program demonstrates early positive outcomes in safety and efficacy, offering real-world insights for policymakers, clinicians, and industry leaders considering regulated psychedelic models.
Sep 03, 2026
Clinical TrialsCYB004, a deuterated DMT analogue, showed longer-lasting psychedelic effects and acceptable safety in a Phase 1 trial, but did not resolve pharmacokinetic variability—raising important questions for next-generation tryptamine development.
Sep 03, 2026
PolicyNew Zealand authorizes two psychiatrists to prescribe MDMA for PTSD, moving beyond research trials to real-world clinical use. This decision sets a precedent for future regulatory, clinical, and insurance frameworks in psychedelic medicine.
Sep 03, 2026
NeuroscienceA new review synthesizes evidence on 11β-HSD enzymes in PTSD, revealing their role in local brain glucocorticoid metabolism. These insights may inform future psychiatric drug development and clinical trial design.
Sep 03, 2026
NeuroscienceA 2026 review details how Drosophila models are unlocking genetic and neural mechanisms behind sleep impairments in stimulant use disorder, offering foundational insights for future pharmacological and translational research.
Sep 03, 2026
NeuroscienceUT MD Anderson's new animal study finds psilocybin may prevent chemotherapy-induced nerve injury, highlighting a possible future role in oncology care. While promising, the research is preclinical, and significant regulatory and translational hurdles remain.
Sep 03, 2026
PolicyU.S. psychiatrists are now authorized to prescribe MDMA for PTSD, signaling a new era in mental health treatment. This policy shift will impact insurance, provider training, and regulatory oversight, while raising key questions about safety, efficacy, and long-term monitoring.
Sep 03, 2026
NeuroscienceA new review maps the mechanisms and disease links of silent synapse activation, highlighting implications for neuroplasticity, depression, and addiction—key areas for psychedelic research.
Sep 03, 2026
Clinical TrialsA new review synthesizes clinical and policy evidence on ketamine, cannabinoids, and psychedelics for opioid use disorder, finding early promise but significant safety and regulatory hurdles. Rigorous trials and policy reform are needed.
Sep 03, 2026
MarketA wave of donor funding is transforming psychedelic research as FDA approval approaches, expanding opportunities but also raising questions about influence, priorities, and equitable access in the field.
Sep 03, 2026
Clinical TrialsPhase 1 trials of BI 1569912, a GluN2B-selective NMDA receptor negative allosteric modulator, found favorable safety and pharmacokinetics in healthy adults, with no dissociation or serious adverse events, informing CNS drug research.
Sep 02, 2026
Clinical TrialsRecent clinical trial data suggest ketamine may offer antidepressive benefits for refractory bipolar depression, a population with few effective options. This analysis examines the findings, mechanisms, policy implications, and outstanding risks.
Sep 02, 2026
Clinical TrialsInitial studies indicate psilocybin therapy could help treat cocaine addiction, potentially expanding psychedelic-assisted treatments. Larger, controlled trials and regulatory guidance will determine its future clinical role.
Sep 02, 2026
Clinical TrialsA randomized controlled trial in Ontario found that serial IV ketamine infusions significantly reduced depressive symptoms in treatment-resistant bipolar depression, with a favorable safety profile and no observed mania or psychosis, supporting expanded clinical use.
Sep 02, 2026
Clinical TrialsA new scoping review (2026) maps six psychological mechanisms underpinning psychedelic-assisted therapy for substance use disorders, emphasizing the complex, interacting processes and the need for rigorous causal research.
Sep 02, 2026
NeuroscienceA 2026 study reveals distinct nucleus accumbens proteomic signatures tied to stress and antidepressant response in rat strains, highlighting molecular pathways that may inform future precision treatments for depression.
Sep 01, 2026
Clinical TrialsA recent publication highlights how nutrition can influence outcomes in 5-MeO-DMT clinical trials, offering recommendations to enhance trial design, participant safety, and data interpretation.
Sep 01, 2026
Clinical TrialsA 2026 multidimensional review details psilocybin's pharmacology, clinical evidence, safety, and outstanding questions on long-term effects and dosing, highlighting the need for rigorous, standardized research before broader clinical use.
Sep 01, 2026
Clinical TrialsA Brazilian case report details rapid symptom improvement in a patient with treatment-resistant depression following subcutaneous ketamine. While promising, this single case highlights the urgent need for controlled studies to assess safety, efficacy, and broader clinical relevance.
Sep 01, 2026
NeuroscienceA 2026 SEEG study directly maps the human thalamus' functional architecture, providing new insights into thalamo-cortical circuits relevant to neurological and psychiatric research, including future psychedelic interventions.
Sep 01, 2026
Clinical TrialsA Phase 1 trial of oral Ketamir-2, a novel NMDA antagonist, reports strong safety and pharmacokinetics with no dissociative or abuse signals, supporting further development for neuropathic pain and neuropsychiatric disorders.
Sep 01, 2026
Clinical TrialsA 2026 review consolidates evidence that psilocybin enhances neuroplasticity and improves symptoms in treatment-resistant depression, but underscores the need for further trials and regulatory clarity.
Sep 01, 2026
Public HealthA new study identifies key demographic and psychological factors influencing intentions to use psilocybin for mental health, including a marked preference for natural over synthetic formulations. These findings may shape clinical trial recruitment and policy if psilocybin is FDA-approved.
Sep 01, 2026
NeuroscienceA September 2026 study shows that combining molecular-enriched functional connectivity with structural MRI improves brain-age prediction, linking aging to dopamine and serotonin systems. This approach may inform future psychedelic trials and biomarker discovery.
Sep 01, 2026
NeuroscienceRecent research uncovers how MHC class II upregulation in dopaminergic neurons leads to GABAergic synapse pruning in neurodevelopmental disorders, highlighting a novel neuroimmune mechanism with potential implications for future psychedelic and neuropsychiatric studies.
Sep 01, 2026
NeuroscienceA recent paper critiques the broad use of 'plasticity' in psychedelic research, proposing the MR-P framework to clarify links between brain changes and mental health outcomes. This shift may influence trial design, regulatory review, and translational impact.
Sep 01, 2026
Clinical TrialsA qualitative analysis of psilocybin therapy for treatment-resistant OCD finds that psychological engagement, such as surrender and self-compassion, may drive positive outcomes more than the intensity of the psychedelic experience itself.
Sep 01, 2026
NeuroscienceA 2026 study finds that ERA-based 40-Hz auditory steady-state response (ASSR) profiling reveals neural synchrony deficits in mood and psychotic disorders, supporting pragmatic biomarker development for patient stratification and outcome measurement in psychiatric and psychedelic research.
Sep 01, 2026
NeuroscienceA September 2026 mouse study identifies the IL → RE → vHIPP brain circuit as essential for antidepressant and ketamine-induced neuroplasticity, offering mechanistic insight for novel psychiatric therapies and biomarker discovery.
Sep 01, 2026
Clinical TrialsA 2026 structured review identifies ongoing regulatory, methodological, and translational challenges in clinical trials of ketamine and psilocybin for depression, emphasizing the need for more robust, integrated evidence before clinical adoption.
Sep 01, 2026
NeuroscienceThe determination of psilocybin's single-crystal structure could improve formulation stability and aid therapeutic research.
Sep 01, 2026
Clinical TrialsStanford's study on ketamine's impact on OCD may reveal new neurobiological insights, enhancing treatment strategies.
Sep 01, 2026
Clinical TrialsRecent evidence reveals that female sex hormones significantly influence psilocybin's effects, with preclinical data warning of postpartum risks and possible PMDD benefits. The lack of stratified human data calls for urgent integration of hormonal tracking in future trials.
Aug 31, 2026
Public HealthA new case report details ketamine-induced bladder injury in a pediatric patient, raising safety questions as ketamine use rises. This briefing examines mechanisms, policy implications, and research priorities for clinicians and regulators.
Aug 31, 2026
PolicyThe DEA’s recent engagement with marijuana businesses on federal rescheduling protections highlights regulatory strategies that may inform future oversight of psychedelics. This development signals evolving compliance expectations and potential precedents for controlled substance reform.
Aug 31, 2026
NeuroscienceA novel behavioral task (CoMET) demonstrates how motivation to exert effort is shaped by reward context and controllability, informing future clinical and psychedelic research into motivation deficits seen in disorders like depression.
Aug 31, 2026
Clinical TrialsA major 2026 review confirms strong clinical trial evidence for psilocybin in depression and MDMA in PTSD, but highlights critical gaps in sample diversity, follow-up, and safety monitoring that must be addressed for broader clinical adoption.
Aug 31, 2026
Clinical TrialsThis analysis explores the integration of psychedelics in healthcare, focusing on both biomedical and existential roles, and discusses implications for clinical trials and public health.
Aug 31, 2026
Clinical TrialsCombining ketamine with psychotherapy shows promise in enhancing mental health treatments, but further research is needed to understand risks and efficacy.
Aug 31, 2026
NeuroscienceA study reveals the complex relationship between breathing and neural oscillations, potentially impacting cognitive and mental health therapies.
Aug 31, 2026
Public HealthPhiladelphia's response to medetomidine in opioids highlights the need for enhanced overdose response and clinical strategies.
Aug 31, 2026
Clinical TrialsA new framework organizes psychedelic and neuropsychiatric therapies by mechanism, offering a standardized reference for practitioners.
Aug 31, 2026
LegalThe FDA's debarment of Dr. Rahim Shafa emphasizes strict regulatory enforcement, impacting compliance strategies in the psychedelic sector.
Aug 31, 2026
NeuroscienceA 2026 PubMed review details ketamine's effects on memory, from synaptic changes to brain circuits, with implications for clinical use, trial design, and policy. The model informs risk-benefit decisions as ketamine's clinical footprint grows.
Aug 30, 2026
Clinical TrialsA new systematic review (Aug 2026) synthesizes published studies on ketamine and esketamine for treatment-resistant depression, highlighting efficacy, safety, research gaps, and policy implications for clinicians and stakeholders.
Aug 30, 2026
NeuroscienceCurrent treatments for major depressive disorder (MDD) often fall short, prompting exploration of novel approaches focusing on neuroplasticity and neurocircuitry.
Aug 30, 2026
NeuroscienceThis review examines the complex mechanisms linking chronic low back pain and major depressive disorder, highlighting the potential of precision medicine in improving treatment outcomes.
Aug 30, 2026
Clinical TrialsKetamine infusions show promise for treatment-resistant bipolar depression but require more targeted research and individualized strategies.
Aug 30, 2026
NeuroscienceA recent study maps brain networks involved in dissociative symptoms, potentially influencing psychedelic research on similar neural pathways.
Aug 29, 2026
NeuroscienceResearch on Tibetan monks shows meditation's neurophysiological effects, suggesting mental health benefits but highlighting study design limitations.
Aug 29, 2026
Clinical TrialsA new PubMed study surveys US oncology providers' perspectives on psychedelic-assisted therapy, revealing both optimism and caution. Findings highlight key adoption barriers and inform future clinical trial, policy, and reimbursement strategies.
Aug 28, 2026
NeuroscienceKetamine shows promise in treating resistant depression by modulating NMDA and AMPA receptors, enhancing neuroplasticity.
Aug 28, 2026
Clinical TrialsA systematic review highlights MDMA-assisted therapy's potential to alleviate depressive symptoms in PTSD, possibly influencing clinical guidelines.
Aug 28, 2026
Clinical TrialsA new study compares psychedelics' effectiveness and safety in psychiatry, using intranasal esketamine as a benchmark, to guide future research and clinical practices.
Aug 28, 2026
NeuroscienceUnderstanding ECT's brain network changes may inform psychedelic therapy research, enhancing treatment strategies and patient response predictions.
Aug 28, 2026
NeuroscienceRNA sequencing is advancing the understanding of depressive disorders, revealing molecular mechanisms, but faces hurdles in clinical application.
Aug 28, 2026
Public HealthA study using LC-MS/MS hair analysis reveals prevalent polysubstance use at Brazilian EDM festivals, emphasizing the need for enhanced public health strategies.
Aug 28, 2026
Clinical TrialsThis review examines interoceptive interventions' role in reducing anxiety sensitivity, highlighting potential therapeutic benefits and research needs.
Aug 28, 2026
NeuroscienceA review examines natural medicines' role in neurogenesis for depression, highlighting the need for biomarker-stratified trials and safety assessments.
Aug 28, 2026
NeuroscienceLipid metabolism disruptions can alter fluoxetine's efficacy, impacting treatment-resistant depression. Understanding these mechanisms may improve therapies.
Aug 28, 2026
PolicyHeidi Overton's FDA nomination could reshape psychedelic policies, affecting research and market dynamics.
Aug 28, 2026
LegalA legal dispute over a psilocybin measure in Joseph, Oregon, may influence future psychedelic regulations.
Aug 28, 2026
Public HealthTampa Bay's expansion of ketamine therapy access for veterans with PTSD marks a pivotal move in mental health care, potentially influencing broader psychedelic therapy adoption.
Aug 28, 2026
Clinical Trials5-MeO-DMT may offer new hope for treatment-resistant depression, but further research is needed to confirm its efficacy and safety.
Aug 27, 2026
Clinical TrialsPsilocybin shows promise as an emerging therapy for treatment-resistant depression, complementing existing treatments like ketamine.
Aug 27, 2026
Clinical TrialsJapanese versions of MEQ-4 and CEQ-7 facilitate efficient assessment of mystical and challenging experiences in psychedelic studies.
Aug 27, 2026
NeurosciencePsilocybin enhances sociability in ASD mouse models without requiring wakefulness, potentially minimizing psychedelic side effects.
Aug 27, 2026
Clinical TrialsA study in Las Vegas shows ayahuasca may reduce depression symptoms, but further research is needed to confirm and understand these effects.
Aug 27, 2026
NeuroscienceA study reveals a beta-band neural signature post-psychedelic use, suggesting new biomarkers for understanding and enhancing therapeutic applications.
Aug 27, 2026
Clinical TrialsA systematic review suggests ketamine may be effective for OCD, prompting potential shifts in clinical guidelines and research directions.
Aug 27, 2026
NeuroscienceOLFM1 gene hypomethylation is linked to depression, offering insights into genetic and environmental influences. This discovery could inform future therapeutic approaches, including psychedelics.
Aug 27, 2026
MarketThe AMCP panel discusses psilocybin's potential for TRD, emphasizing data needs and network readiness for mental health care.
Aug 27, 2026
PolicyOregon's psilocybin centers prioritize safety through psychiatric assessments but face financial challenges impacting scalability and accessibility.
Aug 27, 2026
Clinical TrialsA pilot study compares high dose Δ9-THC and psilocybin, revealing similar psychedelic experiences under controlled conditions.
Aug 27, 2026
PolicyDEA's Schedule IV classification of cipepofol supports medical use with regulatory controls, balancing access and safety.
Aug 27, 2026
PolicyThe DEA's temporary Schedule I placement of four compounds restricts research and market activities, citing public safety concerns.
Aug 27, 2026
Public HealthOregon's legal psilocybin therapy has treated 20,000 people with positive outcomes, potentially shaping future policies and research.
Aug 27, 2026
NeuroscienceUnderstanding the BDNF–TrkB–mTOR axis in depression could lead to more targeted treatments, emphasizing the role of neuroinflammation and oxidative stress.
Aug 26, 2026
NeuroscienceiPSC-derived neuronal models offer new insights into psychiatric disorders, aiding precision psychiatry, but face challenges in modeling complex genetic factors.
Aug 26, 2026
Clinical TrialsKetamine shows promise for treatment-resistant depression, but concerns about safety and long-term use persist, requiring careful patient selection.
Aug 26, 2026
Clinical TrialsRapamycin shows potential in enhancing ketamine treatment, but variability in patient response underscores the need for further research.
Aug 26, 2026
NeuroscienceSmall molecules are reshaping pain and mental health care, offering new therapeutic strategies with fewer side effects.
Aug 26, 2026
Clinical TrialsPhase II/III trials explore diverse mechanisms in next-gen pharmacotherapies for unipolar mood disorders, highlighting potential and challenges.
Aug 26, 2026
PolicyA federal report encourages states to prepare for FDA approval of psychedelics, impacting policy and healthcare integration.
Aug 26, 2026
PolicyEPA's SNURs under TSCA require 90-day notices for new uses of certain chemicals, impacting psychedelic research.
Aug 26, 2026
MarketA new ketamine clinic in Kitsap, Washington, aims to improve access to psychedelic-assisted therapy for treatment-resistant conditions.
Aug 26, 2026
PolicyThe comment period extension for 7-OH's Schedule I proposal impacts research and legal access.
Aug 26, 2026
PolicyThe FDA invites public comments on the scheduling of eight substances, impacting international drug control and medical availability.
Aug 26, 2026
PolicyDEA's temporary Schedule I classification of mitragynine derivatives raises regulatory hurdles for research and industry, citing public safety risks.
Aug 26, 2026
Clinical TrialsA new case report describes S-ketamine use for suicidal ideation in an adolescent with early-onset psychosis, underscoring the need for controlled trials and careful policy consideration in this vulnerable group.
Aug 25, 2026
PolicyA 2026 PubMed study compares state psilocybin regulatory frameworks, highlighting key differences in access, oversight, and market design. The analysis offers actionable insights for policymakers and researchers navigating evolving psychedelic laws.
Aug 25, 2026
NeuroscienceA recent study reveals how substance use may influence the relationship between stress hormones and brain white matter, offering potential insights into substance use disorder.
Aug 25, 2026
Clinical TrialsAs psychedelic treatments reduce clinical intensity, social environments may play a crucial role in patient outcomes, suggesting new research and care strategies.
Aug 25, 2026
NeuroscienceCreatine monohydrate shows promise in enhancing cognitive function under stress and as an adjunct in treating unipolar depression.
Aug 25, 2026
NeuroscienceNew research suggests tryptophan metabolism via the gut-brain axis may classify subtypes of depression, paving the way for tailored treatments.
Aug 25, 2026
Clinical TrialsEsketamine, when used with fascia iliaca block, improves postoperative analgesia in elderly hip surgery patients, suggesting potential guideline updates.
Aug 25, 2026
PolicyState approaches to psilocybin regulation vary significantly, with New Mexico's clinician-directed model offering a promising foundation for future policies.
Aug 25, 2026
NeuroscienceWearable vagus nerve stimulation (VNS) offers a promising non-invasive approach for treating depression, potentially overcoming limitations of implantable systems.
Aug 25, 2026
Clinical TrialsSalvinorin A shows a favorable safety profile in human trials, with no serious adverse events reported, suggesting potential for further research.
Aug 25, 2026
Clinical TrialsS-ketamine shows promise for treating depression in adolescents with early-onset psychosis, suggesting new research avenues.
Aug 25, 2026
NeuroscienceStudy shows DOI affects mice's olfactory search behavior, suggesting broader sensory impacts of psychedelics.
Aug 25, 2026
NeuroscienceA systematic review shows multi-omics integration can redefine major depressive disorder, suggesting biomarker-based diagnostics and personalized treatments.
Aug 25, 2026
MarketFilament Health's agreement to supply PEX01 could enhance psilocybin access for research, impacting clinical trials and market growth.
Aug 25, 2026
Clinical TrialsUW's trial on psilocybin retreats for cancer patients explores psychedelics' role in palliative care, impacting future clinical practices.
Aug 25, 2026
Clinical TrialsRhelion Life Sciences' agreement with UW aims to boost psilocybin research, potentially accelerating therapeutic developments.
Aug 25, 2026
PolicyOregon's psychedelic dataset surpasses historical trials, urging federal regulators to incorporate state data into policy decisions.
Aug 25, 2026
Public HealthThis review explores the complex relationship between medicinal plants and spirituality, highlighting the need for integrative research in traditional health practices.
Aug 24, 2026
NeuroscienceResearch highlights traditional pharmacopoeias' empirical accuracy, particularly in Amazonian ayahuasca, suggesting a framework for future ethnopharmacological studies.
Aug 24, 2026
NeuroscienceEmerging therapies for depression in Crohn's disease target the gut-brain axis, but require further research to confirm efficacy and safety.
Aug 24, 2026
Clinical TrialsThe STAR and TextSTAR programs show promise as feasible and acceptable interventions for recent sexual assault survivors, potentially reducing PTSD and substance misuse.
Aug 24, 2026
NeuroscienceRecent research uncovers arrestins as complex integrators in GPCR signaling, opening pathways for advanced drug design targeting neurological disorders.
Aug 24, 2026
NeuroscienceAyahuasca shows promise as a multitarget therapeutic for neuropsychiatric disorders, but variability and algorithmic challenges remain.
Aug 24, 2026
NeuroscienceRecent findings suggest prolonged gabapentin use may increase neurodegenerative risks, necessitating further research into mechanisms and protective strategies.
Aug 24, 2026
NeuroscienceA study finds EV proteomics may reveal unique pathways in treatment-resistant depression, aiding molecular stratification.
Aug 24, 2026
PolicyThe FDA's faster movement on psychedelics may hasten approvals, but calls for more legislative action highlight ongoing challenges.
Aug 24, 2026
Clinical TrialsA systematic review protocol examines how baseline BMI affects outcomes in treatment-resistant depression, influencing personalized treatment strategies.
Aug 24, 2026
MarketCMPS's stock surge reflects investor optimism about FDA hearing outcomes, potentially reshaping psychedelic therapy regulations and market paths.
Aug 24, 2026
NeuroscienceRecent findings confirm ketamine's interaction with opioid receptors, impacting its classification and therapeutic guidelines.
Aug 24, 2026
PolicyOregon's psilocybin legalization offers a model for other regions, highlighting regulatory trends and community impacts.
Aug 24, 2026
Clinical TrialsPsilocybin's transition from lab success to clinical application faces significant challenges, impacting its therapeutic potential and industry growth.
Aug 24, 2026
Clinical TrialsA new patent application for MDMA-N-Acylethanolamines aims to treat PTSD, anxiety, and eating disorders, with potential impacts on research and commercialization.
Aug 24, 2026
Clinical TrialsNeuroThera and Clearmind's partnership to develop MDMA-PTSD treatments highlights growing federal support and potential market shifts.
Aug 24, 2026
NeuroscienceDMT's simple structure belies its profound effects on consciousness, posing both therapeutic potential and significant research challenges.
Aug 23, 2026
NeuroscienceDMT, a psychoactive compound, is studied for its unique effects and potential therapeutic uses, yet its biological functions remain elusive.
Aug 23, 2026
Clinical TrialsA meta-analysis finds a weak correlation between trait responsiveness to verbal suggestions and placebo effects, with implications for psychedelic research.
Aug 23, 2026
MarketMissouri's inaugural ketamine clinic signals growing acceptance of psychedelic therapies, potentially setting a model for future practices.
Aug 23, 2026
Clinical TrialsA new review highlights psilocybin's promise in treating depression, showing faster and significant symptom reduction, particularly in treatment-resistant cases.
Aug 22, 2026
NeurosciencePsilocybin affects brain networks differently in autistic individuals, highlighting potential for tailored therapies in autism spectrum disorders.
Aug 22, 2026
Public HealthA 2026 PubMed review details ketamine-induced uropathy, highlighting pathophysiology, clinical risks, and emerging treatments. As ketamine access grows, monitoring, informed consent, and further research are essential for public health and policy.
Aug 21, 2026
MarketTripTally provides a flexible tool for estimating labor costs in psychedelic-assisted psychotherapy, crucial for informed decision-making.
Aug 21, 2026
PolicyA federal audit reveals Kansas Medicaid MCOs' non-compliance with parity laws, potentially affecting access to psychedelic treatments.
Aug 21, 2026
Public HealthOver 2,300 psilocybin users in Oregon and Colorado provide insights into real-world effects, informing policy and health strategies.
Aug 21, 2026
Clinical TrialsKetamine shows no significant impact on appetite or weight in mood disorder patients, supporting its metabolic safety for clinical use.
Aug 21, 2026
MarketTripTally addresses a critical gap in economic planning for psychedelic therapy by enabling stakeholders to estimate labor costs based on specific staffing and wage conditions.
Aug 21, 2026
NeuroscienceCB1 allosteric modulators show promise for pain relief and addiction treatment with reduced misuse risk, but require further research and standardization.
Aug 21, 2026
Clinical TrialsExploring new trial designs for psychedelic research to address pretreatment expectancy and double-blind limitations.
Aug 21, 2026
PolicyOregon's psilocybin program treated 346 people, revealing therapeutic potential and operational challenges, influencing future psychedelic policies.
Aug 21, 2026
Clinical TrialsMDMA shows promise for neuropathic pain, with unique mechanisms and lasting effects. Dedicated trials could transform pain management strategies.
Aug 21, 2026
Clinical TrialsOHSU's study on psilocybin reveals potential therapeutic benefits for anxiety, depression, and PTSD, possibly influencing future clinical practices and regulations.
Aug 21, 2026
Clinical TrialsMDMA shows promise for neuropathic pain relief, with a review outlining mechanisms and trial strategies for future research.
Aug 21, 2026
Clinical TrialsA JAMA study explores Oregon's psilocybin services, revealing key insights into benefits and risks outside clinical trials.
Aug 21, 2026
PolicyA recent executive order by Trump facilitates federal support for psychedelic research, potentially altering clinical trials and public health policies.
Aug 21, 2026
Clinical TrialsPsychedelic trials struggle with assumptions about expectancy and double-blind procedures, impacting causal identification. New designs may improve validity.
Aug 20, 2026
NeuroscienceStudy finds robust visuomotor mismatch EEG responses in humans, simplifying experimental setups and enhancing predictive coding research.
Aug 20, 2026
Clinical TrialsA phase two trial investigates 60-Hz flickering white light for depression, highlighting potential non-drug treatments.
Aug 20, 2026
NeuroscienceResearch suggests insulin resistance may influence major depressive disorder, highlighting the need for metabolic screening in treatment strategies.
Aug 20, 2026
Public HealthPsychedelics may offer mental health benefits for Nevada veterans and responders, but legislative and clinical clarity is needed.
Aug 20, 2026
Clinical TrialsA narrative review highlights neuromodulation as a promising pathway for treatment-resistant depression, emphasizing the need for a multidimensional clinical framework.
Aug 20, 2026
Clinical TrialsPsilocybin shows promise in treating mental illnesses, but faces significant regulatory and funding barriers in the US.
Aug 20, 2026
NeurosciencePsilocybin alters hippocampal sharp-wave ripples, affecting memory processing and raising questions about therapeutic applications.
Aug 20, 2026
Clinical TrialsA recent trial highlights psilocybin's potential to alter personality traits in alcohol use disorder, suggesting new therapeutic pathways.
Aug 20, 2026
Clinical TrialsOregon's psilocybin study shows significant reductions in depression and anxiety, potentially shaping future public health policies and research.
Aug 20, 2026
Clinical TrialsA study finds long-term benefits from Oregon's psilocybin services, influencing mental health policy and market dynamics.
Aug 19, 2026
NeuroscienceA review highlights inflammation's role in depression, affecting 25% of patients. Precision medicine could optimize treatment efficacy.
Aug 19, 2026
Clinical TrialsEHR-based models for predicting treatment-resistant depression struggle with transportability across health systems, highlighting data biases and clinical heterogeneity.
Aug 19, 2026
NeuroscienceRepetitive transcranial magnetic stimulation (rTMS) shows potential for psychiatric disorders, but lacks standardized parameters and biomarkers, limiting clinical use.
Aug 19, 2026
NeuroscienceA recent study highlights the potential of a dextromethorphan-bupropion combination in treating major depressive disorder, showing significant improvements in a mouse model.
Aug 19, 2026
Clinical TrialsA systematic review finds current psilocybin microdosing studies lack rigor, urging well-designed trials to inform policy and practice.
Aug 19, 2026
PolicyTrump's plan for psychedelic treatments for veterans may shift federal policy, impacting research funding and regulatory pathways.
Aug 19, 2026
NeurosciencePsilocybin affects brain-wide circuit dynamics through 5-HT2A receptors, emphasizing burst firing patterns, not mean firing rates.
Aug 19, 2026
Clinical TrialsOregon's psilocybin services show promise in improving mental health outcomes, with high satisfaction and few adverse reactions, influencing potential policies elsewhere.
Aug 19, 2026
PolicyA real-world study of Oregon's psilocybin program reveals promising outcomes, influencing future policy and public health strategies.
Aug 19, 2026
NeuroscienceResearch shows psychedelics align brain activity with environmental context, offering insights for therapeutic use and clinical trial design.
Aug 19, 2026
PolicyOverton's nomination as FDA head may accelerate psychedelic research but raises concerns about vaccine policy.
Aug 19, 2026
Public HealthOregon's legal psilocybin program, involving over 20,000 participants, offers key insights for future policy and public health strategies.
Aug 19, 2026
Clinical TrialsThe VA's psilocybin trial for veterans with treatment-resistant depression may influence future mental health policies and therapies.
Aug 19, 2026
Clinical TrialsA recent study highlights ketamine and esketamine's potential in managing postoperative pain in gynecological surgeries, suggesting expanded therapeutic roles.
Aug 18, 2026
Clinical TrialsA study highlights psilocybin's effects on older adults, informing guidelines for safe use in state-regulated services.
Aug 18, 2026
Clinical TrialsA Cochrane review protocol evaluates ketamine and esketamine for post-op pain in gynecological surgery, aiming to reduce opioid reliance.
Aug 18, 2026
Clinical TrialsA new trial examines esketamine administration routes for managing postoperative hyperalgesia in elderly patients, revealing potential improvements in surgical pain strategies.
Aug 18, 2026
Clinical TrialsA recent fMRI trial shows ketamine alters brain dynamics linked to rumination, highlighting glutamatergic mechanisms and potential antidepressant applications.
Aug 18, 2026
Clinical TrialsA critique reveals methodological flaws in studies on psychedelics' abuse liability, urging more robust research to inform policy.
Aug 18, 2026
Clinical TrialsIsotryptamine analogs, including isoDMT, are being tested for their psychotherapeutic potential, entering clinical trials as novel serotonergic agents.
Aug 18, 2026
Public HealthKetamine therapy's growth in South Florida reflects increased acceptance of psychedelics in mental health care, with potential policy and market impacts.
Aug 18, 2026
EthicsA recent study emphasizes the need for caution in expanding psychedelic-assisted therapy, highlighting ethical and safety concerns.
Aug 18, 2026
Clinical TrialsA systematic review supports the long-term safety of ketamine and esketamine for treatment-resistant depression, with no organ toxicity or addiction risk.
Aug 17, 2026
Public HealthKetamine therapy's arrival in Aventura, Florida, marks a significant step in integrating alternative medicine into mainstream healthcare, raising questions about regulation and efficacy.
Aug 17, 2026
Clinical TrialsKetamine therapy is gaining traction for mental health treatment, with implications for clinical protocols and patient care strategies.
Aug 17, 2026
Clinical TrialsPsilocybin-assisted psychotherapy shows promise for treating substance use disorders, but larger trials are needed to validate findings and understand mechanisms.
Aug 17, 2026
Clinical TrialsThe Birmingham VA's psilocybin trial could redefine treatment for veterans with depression, influencing future policies and clinical practices.
Aug 17, 2026
PolicyCanada's fragmented policy landscape complicates the integration of psychedelic-assisted therapy in cancer care, despite growing evidence and demand.
Aug 17, 2026
PolicyPolicy fragmentation in Canada poses challenges for integrating psychedelic-assisted therapy in cancer care, despite existing federal access mechanisms.
Aug 17, 2026
Clinical TrialsEsketamine's evolving clinical use could alter depression treatment protocols, impacting prescribing practices and patient access.
Aug 17, 2026
NeuroscienceA new study proposes a clear definition of 'psychedelic', potentially influencing research and regulatory frameworks.
Aug 17, 2026
Clinical TrialsTwo Alabama VA facilities will participate in psilocybin trials, potentially improving mental health care for veterans and expanding psychedelic research.
Aug 16, 2026
Clinical TrialsA new method for preparing ayahuasca using hydroethanolic extraction could lead to more consistent formulations, impacting clinical trials and therapeutic uses.
Aug 16, 2026
NeuroscienceA new method for extracting mescaline from San Pedro cactus reduces preparation volume and viscosity but requires further clinical evaluation.
Aug 16, 2026
NeuroscienceA recent study explores how psychedelics may lead to persisting perceptual abnormalities, impacting safety and therapeutic guidelines.
Aug 16, 2026
EthicsFrantz Fanon's critical phenomenology offers valuable insights into developing culturally informed psychedelic therapies for racialized individuals.
Aug 15, 2026
Clinical TrialsA meta-analysis suggests IV ketamine may quickly reduce depressive symptoms in adolescents, but highlights the need for larger, rigorous trials.
Aug 15, 2026
Clinical TrialsLSD's Phase 3 trial success could transform mental health treatment, yet regulatory and distribution hurdles persist.
Aug 15, 2026
Clinical TrialsMeditation may enhance psychedelic experiences by reducing negative effects, suggesting new clinical protocols.
Aug 15, 2026
PolicyAI integration in psychedelic therapy raises concerns about relational competence and calls for policy updates on accreditation.
Aug 14, 2026
Clinical TrialsA recent study on LSD therapy reveals new insights into its potential benefits, informing future clinical trials and policy decisions.
Aug 14, 2026
Clinical TrialsA new trial investigates psilocybin's efficacy for treating depression in Parkinson's, potentially broadening therapeutic options.
Aug 14, 2026
Clinical TrialsThe VA's study of MDMA, GLP-1s, and psilocybin could transform veteran care, offering new treatments for PTSD and depression.
Aug 14, 2026
Clinical TrialsA new review highlights the complex safety and efficacy of psychedelics, emphasizing the need for rigorous trials and long-term safety studies.
Aug 14, 2026
NeuroscienceResearch on conative inference and allostatic resilience may inform new mental health treatments, integrating desire and affect in brain function.
Aug 14, 2026
PolicyThe Veterans Affairs' advocacy for psychedelics and new FDA guidance may expand access and shape regulations, while MDMA approval faces hurdles.
Aug 14, 2026
Clinical TrialsRhelion and UHN's trial on psilocybin for Parkinson's depression could reshape therapeutic approaches and inform future research and policy.
Aug 14, 2026
Clinical TrialsNew research shows low-dose ketamine alters biomarkers in MDD and PTSD, indicating potential for shared treatment protocols.
Aug 14, 2026
Clinical TrialsrTMS may offer a safe alternative for antenatal depression, but further research is needed to confirm its efficacy and safety.
Aug 14, 2026
NeuroscienceA new model integrates psychoanalysis with computational neuroscience, offering potential advancements in precision psychiatry, yet requires empirical validation.
Aug 14, 2026
Clinical TrialsA systematic review highlights cognitive changes post-psychedelic use, informing research and policy on therapeutic potential.
Aug 14, 2026
PolicyThe 2026 Unified Agenda outlines potential regulatory actions impacting psychedelic research, emphasizing the need for stakeholders to stay informed.
Aug 14, 2026
PolicyThe DEA's updated exemptions list impacts psychedelic research, availability, and compliance under the Controlled Substances Act.
Aug 14, 2026
PolicyThe FDA's PDUFA reauthorization could affect timelines and costs for psychedelic drug approvals, offering stakeholders a chance to influence outcomes.
Aug 14, 2026
Clinical TrialsResearch shows psychologists' personal MDMA use affects their attitudes towards its therapeutic application, stressing the need for evidence-based training.
Aug 13, 2026
Clinical TrialsThe combination of ketamine and psychotherapy shows promise in treating chronic neuropathic pain, potentially expanding psychedelic applications.
Aug 13, 2026
Clinical TrialsThe PREPP workshop highlights the role of veteran peer support in psychedelic therapy, improving readiness and collaboration in clinical settings.
Aug 13, 2026
Clinical TrialsThe VA's psilocybin trial aims to address PTSD and depression in veterans, marking a pivotal moment in psychedelic research and mental health treatment.
Aug 13, 2026
Public HealthA recent review debunks the myth of Amanita muscaria as a common suicide method, emphasizing the role of biases and the need for accurate public health information.
Aug 13, 2026
NeuroscienceRGS6 is identified as a crucial modulator of cannabinoid effects on gastrointestinal motility and pain in mice, with implications for future therapies.
Aug 13, 2026
Clinical TrialsA multicenter study in Portugal reveals the challenges of treating treatment-resistant depression, emphasizing the need for novel therapies.
Aug 13, 2026
NeuroscienceWNK kinases may enhance cognitive functions by modulating insulin signaling in the brain, offering new avenues for treating cognitive impairments.
Aug 13, 2026
NeuroscienceWNK kinases influence brain glucose uptake and behavior, offering insights into mood and cognitive disorder research.
Aug 13, 2026
NeuroscienceWNK kinases influence learning and anxiety in mice via insulin signaling, suggesting new therapeutic targets for cognitive and mood disorders.
Aug 13, 2026
NeuroscienceWNK kinases affect brain glucose uptake, influencing cognitive functions and mood, with potential therapeutic implications.
Aug 13, 2026
Clinical TrialsThe Nova Protocol examines trauma processing in survivors of the 2023 Nova festival attack, focusing on psychoactive substance exposure.
Aug 13, 2026
Clinical TrialsA new review analyzes the psychological impacts of psychedelic microdosing, highlighting potential benefits and risks.
Aug 13, 2026
Clinical TrialsIntranasal delivery systems for treatment-resistant depression (TRD) offer rapid administration and potential CNS access, but require careful formulation-device integration to ensure therapeutic efficacy and safety.
Aug 13, 2026
Clinical TrialsA systematic review analyzes the psychological effects of psychedelic microdosing, highlighting potential benefits and risks.
Aug 13, 2026
PolicyThe FDA's finalized guidance on formal meetings with drug sponsors under PDUFA aims to streamline the approval process for new psychedelic therapies.
Aug 13, 2026
Clinical TrialsResilient refiles MDMA for PTSD, aiming for regulatory approval. This move could influence both treatment protocols and the psychedelic market.
Aug 12, 2026
Clinical TrialsA survey of Canadian psychiatrists shows support for palliative care in severe mental illness, highlighting quality of life over curative measures.
Aug 12, 2026
NeuroscienceAI systems can influence human belief formation, akin to virtual psychopharmacology, raising ethical and governance concerns.
Aug 12, 2026
NeuroscienceLLMs improve single-cell RNA sequencing for MDD, aiding drug target identification and biomarker discovery, despite challenges.
Aug 12, 2026
NeuroscienceThis analysis explores the NLRP3 inflammasome's role in schizophrenia, highlighting its potential as a biomarker and therapeutic target.
Aug 12, 2026
NeuroscienceA study reveals psilocybin's effects on gut microbiota, suggesting potential mechanisms but no proven clinical benefits for anxiety yet.
Aug 12, 2026
NeuroscienceThe postictal systems window hypothesis offers a new framework for understanding ECT's effects on major depression, focusing on structured recovery phases.
Aug 12, 2026
Clinical TrialsUnderstanding diagnostic pitfalls in treatment-resistant depression can lead to more effective treatments by identifying underlying bipolar spectrum disorders.
Aug 12, 2026
Clinical TrialsA study shows sustained improvements in PTSD, depression, and anxiety in veterans with TBI using magnesium-ibogaine therapy over 12 months.
Aug 12, 2026
NeuroscienceA recent study highlights key differences between DMT and 5-MeO-DMT in neuroplasticity and behavior, suggesting pathways for targeted psychedelic therapies.
Aug 12, 2026
Clinical TrialsThe DREAM protocol offers a novel, non-verbal framework for integrating psilocybin therapy, focusing on embodied and imaginal experiences.
Aug 12, 2026
Clinical TrialsA Phase 2 trial shows taVNS improves cognitive and emotional functions in MCI, suggesting potential for noninvasive treatment.
Aug 12, 2026
Clinical TrialsA recent study shows MDMA-enhanced exposure therapy reverses PTSD-like features in mice, suggesting potential for clinical trials.
Aug 12, 2026
Clinical TrialsPsilocybin services in Oregon and Colorado show mental health improvements but raise safety concerns, highlighting the need for further research.
Aug 12, 2026
Public HealthThis study explores how community insights can shape effective harm reduction and therapeutic practices for psychedelic use.
Aug 12, 2026
PolicyThe DEA's temporary scheduling of O-DSMT as a Schedule I substance imposes strict controls, affecting research and industry activities.
Aug 12, 2026
NeuroscienceLow-dose stereotactic radiosurgery may increase cortical excitability, offering potential for treating neuronal disorders, but safety remains a concern.
Aug 11, 2026
EthicsA study highlights ethical challenges in neurotechnology, emphasizing user-centered approaches to bridge innovation and public concerns.
Aug 11, 2026
Clinical TrialsPsilocybin shows promise in a small trial for anorexia, potentially increasing openness to recovery. Further research is needed.
Aug 11, 2026
NeuroscienceDMT shows promise as a therapeutic agent for ischemic stroke by reducing neuroinflammation through specific receptor pathways in microglia.
Aug 11, 2026
NeuroscienceA new framework suggests arts engagement can improve health by recalibrating physiological regulation, offering insights into non-pharmacological mental health interventions.
Aug 11, 2026
PolicyPsychedelic therapy shows promise for depression, but regulatory and infrastructural barriers hinder its mainstream adoption.
Aug 11, 2026
Clinical TrialsPsychedelic therapy shows promise for depression but faces significant barriers to hospital integration, requiring regulatory and ethical solutions.
Aug 11, 2026
PolicyThe DEA proposes moving suvorexant, lemborexant, and daridorexant from Schedule IV to Schedule V, potentially easing research and market access.
Aug 11, 2026
NeuroscienceResearch highlights sex differences in serotonergic signaling, suggesting personalized approaches in psychedelic therapies may optimize outcomes.
Aug 10, 2026
NeuroscienceQuNex recipes standardize neuroimaging workflows, aiding reproducibility and transparency in psychedelic research by documenting processes in a replicable format.
Aug 10, 2026
Clinical TrialsDifferent outcome measurements can lead to varying interpretations of ketamine's efficacy in treating treatment-resistant depression, highlighting the need for standardized assessment tools.
Aug 10, 2026
Clinical TrialsMAPS' progress with the FDA on MDMA therapy for PTSD could influence regulatory pathways, clinical use, and market dynamics.
Aug 10, 2026
Clinical TrialsNHS trial reveals single-dose psilocybin may aid treatment-resistant depression, impacting future research and regulatory strategies.
Aug 10, 2026
NeuroscienceReview highlights glutamatergic pathways in MS models as therapeutic targets. However, clinical trials show no disease-modifying effects, indicating a significant translational gap.
Aug 10, 2026
NeuroscienceA study using [11C]K-2 PET imaging reveals AMPA receptor patterns across psychiatric disorders, offering insights but not individual diagnostic tools.
Aug 10, 2026
Clinical TrialsPsychedelics show potential in psychiatry, but clinical translation faces hurdles in research, policy, and public perception.
Aug 10, 2026
Clinical TrialsThe PsiMenis trial investigates psilocybin's effects across menstrual cycles, addressing a key gap in psychedelic research and potential treatment improvements.
Aug 10, 2026
Clinical TrialsPropofol shows promise as a treatment for depression, but challenges in dosing, safety, and lack of large trials limit immediate use.
Aug 10, 2026
Clinical TrialsA recent study highlights the benefits and challenges of cotherapy in psilocybin therapy for Generalised Anxiety Disorder, emphasizing safety and therapeutic enhancement.
Aug 10, 2026
Clinical TrialsEsketamine may reduce postoperative delirium in elderly patients by protecting blood-brain barrier integrity and reducing neuroinflammation.
Aug 10, 2026
NeuroscienceNeuroinflammation may define a distinct subtype of MDD, offering new biomarker-guided treatment strategies for resistant cases.
Aug 09, 2026
NeuroscienceA study suggests ketamine may enhance ovarian function in depression models, opening new research avenues in reproductive health.
Aug 08, 2026
NeuroscienceA systematic review links childhood emotional maltreatment to PTSD/CPTSD, highlighting the need for targeted interventions and systematic assessments.
Aug 07, 2026
NeuroscienceNew research suggests that love and empathy may reduce opioid use in OUD patients, offering potential for innovative therapeutic approaches.
Aug 07, 2026
Clinical TrialsA proposal to redefine treatment-resistant schizophrenia may lead to earlier patient identification and expanded clinical trial eligibility.
Aug 07, 2026
Clinical TrialsThis analysis examines treatment-resistant depression, focusing on therapy escalation and diagnostic reassessment strategies.
Aug 07, 2026
Clinical TrialsResearch using FDA data finds no significant link between DXM/BUP antidepressant and diabetes risk, supporting informed clinical decisions.
Aug 07, 2026
Clinical TrialsThis analysis evaluates ketamine and pregabalin's efficacy in managing postoperative pain and reducing opioid use in spinal fusion surgeries.
Aug 07, 2026
Public HealthThis analysis examines barriers in rural Australia's drug treatment, highlighting the need for integrated care and culturally responsive services.
Aug 07, 2026
Clinical TrialsPsilocybin shows promise in nicotine addiction therapy, enhancing neuroplasticity and serotonin receptor activity. Further trials needed.
Aug 07, 2026
Clinical TrialsPsilocybin shows promise in treating phantom limb pain, offering potential new therapeutic pathways beyond mental health applications.
Aug 07, 2026
Clinical TrialsPsilocybin shows promise in treating cluster headaches, but evidence remains preliminary. Further trials are essential to establish efficacy and safety.
Aug 07, 2026
Clinical TrialsConnecticut expands a psilocybin trial to a broader population, indicating potential for treating complex mental health conditions.
Aug 07, 2026
Clinical TrialsA Phase 1 study reveals psilocybin's effects on motor tasks, highlighting dose-dependent safety and feasibility for future therapies.
Aug 07, 2026
Clinical TrialsA systematic review finds ketamine and esketamine safe for long-term use in treatment-resistant depression, with no cumulative organ toxicity or addiction.
Aug 07, 2026
Clinical TrialsA systematic review finds ketamine and esketamine safe for long-term use in TRD, with no organ toxicity or addiction, but calls for standardized safety protocols.
Aug 07, 2026
Clinical TrialsA recent trial in a public healthcare setting shows promise for psilocybin-assisted therapy in treating major depressive disorder.
Aug 06, 2026
Clinical TrialsStandardizing well-being as a primary endpoint in psychedelic trials could enhance comparability and validity, impacting research and patient care.
Aug 06, 2026
Clinical TrialsA new framework suggests low-dose MDMA could optimize cognitive performance, emphasizing minimal effective dosing and risk reduction.
Aug 06, 2026
NeuroscienceEngineered mice models enhance understanding of psychedelics, offering insights into mechanisms and potential therapeutic uses.
Aug 06, 2026
Clinical TrialsKetamine shows non-inferiority to ECT in non-psychotic TRD, offering rapid relief. ECT remains superior for severe psychotic cases.
Aug 06, 2026
NeuroscienceA novel study combines meditation and psychedelics to explore neurocognitive mechanisms of minimal selfhood, using predictive processing and global workspace models.
Aug 06, 2026
Clinical TrialsA new framework for food tracking in psychiatric KMT aims to optimize delivery and patient outcomes by addressing key clinical questions.
Aug 06, 2026
Clinical TrialsVirtual reality shows promise in psychiatric therapy, notably for anxiety and PTSD, but challenges in generalization and personalization remain.
Aug 06, 2026
Public HealthA study on Dutch veterans reveals significant societal costs of PTSD, highlighting the need for targeted mental health interventions.
Aug 06, 2026
Clinical TrialsThis analysis reviews the comparative efficacy of ketamine and ECT in treating treatment-resistant depression, highlighting individualized treatment strategies.
Aug 06, 2026
Public HealthAs psychedelics gain traction, public health strategies must balance safety and therapeutic potential through education, workforce, and data.
Aug 06, 2026
Clinical TrialsA scoping review identifies fragmented methodologies in psychedelic-assisted therapy assessment, highlighting the need for integrated evaluation models.
Aug 06, 2026
Clinical TrialsPsychedelics show promise in treating neurodevelopmental disorders by enhancing neuroplasticity, though evidence remains limited.
Aug 06, 2026
Clinical TrialsA recent analysis highlights mystical experiences, especially positive mood, in MDMA therapy for PTSD, offering insights for future treatment strategies.
Aug 06, 2026
Clinical TrialsA UK NHS trial reveals psilocybin's promise for treatment-resistant depression, suggesting potential for broader application.
Aug 06, 2026
Clinical TrialsShifting focus to well-being in psychedelic trials could reshape FDA policies and enhance therapeutic evaluations.
Aug 06, 2026
NeuroscienceEngineered mice are pivotal in understanding psychedelics' molecular actions, potentially leading to novel neuropsychiatric treatments.
Aug 06, 2026
Clinical TrialsBlinding integrity in psychedelic trials is crucial for reducing bias and ensuring valid outcomes, yet presents unique challenges.
Aug 05, 2026
Clinical TrialsBlinding integrity in psychedelic trials is challenging due to noticeable effects, necessitating innovative designs for unbiased results.
Aug 05, 2026
Clinical TrialsBlinding integrity in psychedelic trials is essential for credible results. Challenges arise from noticeable effects, necessitating innovative solutions for unbiased outcomes.
Aug 05, 2026
Clinical TrialsA single-center study finds rTMS effective for treatment-resistant depression, with long-term benefits in some cases.
Aug 05, 2026
Clinical TrialsA study reveals baseline gene expression differences in ketamine and ECT treatments for TRD, urging larger studies for clearer insights.
Aug 05, 2026
Public HealthThe shift to Brain Health Services in Europe aims to enhance cognitive care for older adults, focusing on prevention and reducing stigma, but faces ethical and access challenges.
Aug 05, 2026
Public HealthExploring ketamine's role in substance use disorder treatment and its impact on youth, with a focus on Australia-specific trends.
Aug 05, 2026
Clinical TrialsHydrogel microneedles offer a promising tool for non-invasive monitoring in psychedelic therapy, though human trials and standardization are needed.
Aug 05, 2026
NeuroscienceA recent study maps excitatory synaptic plasticity induced by psilocybin in mice, revealing potential pathways for antidepressant treatments.
Aug 05, 2026
Clinical TrialsAnalyzing contraindications in MDMA therapy for veterans with PTSD to inform safer clinical practices and future research.
Aug 05, 2026
Clinical TrialsA review of current strategies for treatment-resistant depression highlights the potential of ketamine and esketamine in certain cases.
Aug 05, 2026
Clinical TrialsKetamine shows promise as a treatment for ALS, focusing on sigma-1 receptor modulation and neuroplasticity, but further trials are needed.
Aug 05, 2026
Clinical TrialsA systematic review evaluates psychedelics' efficacy and risks for PTSD, influencing future clinical guidelines and research priorities.
Aug 05, 2026
NeuroscienceNew research suggests targeting 5-HT(2A) receptors could enhance antitumor immunity in colorectal cancer, opening avenues for psychedelic compounds.
Aug 04, 2026
PolicyThe U.S. Executive Order on Psychedelic Therapies could expedite approvals and enhance clinical infrastructure for mental health treatment.
Aug 04, 2026
NeuroscienceA recent EEG study reveals that unusual bodily experiences (UBEs) are linked to increased brain complexity and reduced cortical hierarchy, offering parallels to psychedelic states.
Aug 04, 2026
NeuroscienceA study uses machine learning and fMRI to predict SSRI response in MDD, offering potential for personalized treatment strategies.
Aug 04, 2026
NeuroscienceA recent study supports exercise as a modulator of the lateral habenula, a brain region linked to depression, suggesting potential therapeutic applications.
Aug 04, 2026
Clinical TrialsFemale sex hormones significantly affect the efficacy and tolerability of psychedelics, underscoring the need for targeted research in women's mental health treatments.
Aug 04, 2026
NeuroscienceNew research indicates recreational ketamine use may disrupt salivary gland function, impacting redox and inflammatory homeostasis, with implications for clinical guidelines.
Aug 04, 2026
Clinical TrialsA recent meta-analysis highlights ketamine's potential in CRPS pain management, emphasizing predictors of response for tailored therapies.
Aug 04, 2026
Clinical TrialsEntropy Neurodynamics' TRP-8803 trial may shape the future of psychedelic therapy, influencing clinical practices and market dynamics.
Aug 04, 2026
Clinical TrialsPsilocybin's therapeutic evidence is robust, but outdated clinical guidelines hinder its medical integration, affecting patient care.
Aug 04, 2026
Clinical TrialsA Phase II trial reveals psilocybin's safety and efficacy in supporting cancer treatment, offering insights for future research and policy.
Aug 03, 2026
NeuroscienceA recent study explores dose-effect patterns of psychedelics in rodents, offering insights for future human trials in anxiety-related disorders.
Aug 03, 2026
NeuroscienceResearch highlights GABAergic cells in the zona incerta as key modulators of motivation, offering new therapeutic targets for motivational deficits.
Aug 03, 2026
NeuroscienceGABAergic cells in the zona incerta modulate motivation, presenting new therapeutic targets for treatment-resistant motivational disorders.
Aug 03, 2026
NeuroscienceResearch identifies GABAergic cells in the zona incerta as key modulators of motivation, offering new avenues for addressing motivational deficits.
Aug 03, 2026
NeuroscienceThe Oneness Experience Scale provides researchers with a robust tool to measure spiritual experiences, aiding studies on mindfulness and well-being.
Aug 03, 2026
NeuroscienceGABAergic cells in the zona incerta modulate motivation, offering insights into treatment-resistant motivational deficits and brain function.
Aug 03, 2026
NeuroscienceStudy reveals patient priorities in neurotech design, challenging industry focus on cosmetic features. Insights could guide patient-centered innovations.
Aug 03, 2026
NeuroscienceRecent research identifies GABAergic cells in the zona incerta as key modulators of motivation, offering potential for novel treatments of motivational deficits.
Aug 03, 2026
NeuroscienceRecent rat studies reveal unique brain activity patterns from serotonergic psychedelics, suggesting potential therapeutic applications for neuropsychiatric disorders.
Aug 03, 2026
PolicyThe FDA's finalized guidance on psychedelic drug trials standardizes research, potentially accelerating approvals and investments.
Aug 03, 2026
Public HealthAdvancements in drug detection methods improve forensic and clinical applications, crucial for monitoring new psychoactive substances.
Aug 03, 2026
NeuroscienceNew research explores mechanisms of psychedelic therapy using low-dose psychedelics, breathwork, and vagus nerve stimulation to enhance safety and personalization.
Aug 03, 2026
Clinical TrialsA UK phase 2a trial explores 5-MeO-DMT with CBT for alcohol use disorder, highlighting psychological shifts and potential therapeutic benefits.
Aug 03, 2026
PolicyThe FDA's revised guidance on TDS for ANDAs clarifies in vivo study expectations, affecting psychedelic compound development.
Aug 03, 2026
PolicyThe DEA's proposal to expand the listing of PMK glycidic acid to include esters may impact chemical manufacturing and research compliance.
Aug 03, 2026
NeuroscienceThe psychological control and reserve model offers a nuanced framework for psychotherapy, potentially informing psychedelic-assisted therapy approaches.
Aug 02, 2026
NeuroscienceExploring psilocybin's mechanisms is crucial for optimizing depression treatment, impacting clinical trials and regulatory decisions.
Aug 01, 2026
NeuroscienceA recent study challenges the validity of rodent fear conditioning paradigms in PTSD research, highlighting the need for sex-inclusive models.
Aug 01, 2026
Clinical TrialsA new study highlights psilocybin's potential to reduce fear of cancer recurrence, suggesting implications for clinical guidelines and patient care.
Aug 01, 2026
NeuroscienceA recent study connects ketamine's quick relief of suicidal ideation to increased morning cortisol, opening new research avenues.
Aug 01, 2026
Clinical TrialsA pilot study investigates aspirin and ketamine for acute pain post-knee surgery, highlighting potential shifts in pain management protocols.
Aug 01, 2026
NeuroscienceNew research maps genes responsive to psychedelics, highlighting HTR2A's role in cortical changes, with implications for therapy.
Aug 01, 2026
NeuroscienceA special issue highlights psychedelics' promise in neuropsychiatric drug development, urging further research into their efficacy and safety.
Aug 01, 2026
NeuroscienceStudy shows electrical stimulation mimics ketamine effects in neurons, suggesting potential non-drug therapies for depression.
Aug 01, 2026
Public HealthA new harm-reduction framework addresses acute panic during substance use, focusing on immediate stabilization without equating pharmacological effects.
Jul 31, 2026
Clinical TrialsA new philosophical framework for ketamine-assisted psychotherapy integrates enactivism, challenging existing models and suggesting new research directions.
Jul 31, 2026
NeuroscienceA new model estimates excitation/inhibition balance using M/EEG, offering insights into psychiatric disorders and potential psychedelic research applications.
Jul 31, 2026
NeurosciencePsychedelic-informed therapeutics may offer a novel approach to depression by enhancing synaptic plasticity, bypassing inflammation constraints.
Jul 31, 2026
Clinical TrialsThe Experience-Trajectory Framework offers a nuanced method to improve safety in psychedelic therapy by tailoring protocols to each substance's unique characteristics.
Jul 31, 2026
Clinical TrialsEsketamine infusion reduces sleep disorders and improves recovery in cesarean patients, suggesting new clinical applications.
Jul 31, 2026
PolicyThe FY 2027 Medicare update for Inpatient Psychiatric Facilities could impact the adoption of psychedelic therapies through changes in payment rates and quality measures.
Jul 31, 2026
Clinical TrialsA recent US study indicates psychedelics may aid PTSD treatment in veterans, prompting further research and policy evaluation.
Jul 30, 2026
NeuroscienceA study reveals that elevated magnesium increases neuronal burstiness, challenging its traditional role as a 'burst quieter' and suggesting new therapeutic avenues.
Jul 30, 2026
PolicyThe US is advancing psilocybin legalization through state initiatives, activism, and investment, potentially guiding global efforts.
Jul 30, 2026
Clinical TrialsA recent study in Jamaica explores psychedelic-assisted therapy for racial trauma, emphasizing cultural safety and community affirmation.
Jul 30, 2026
Clinical TrialsThis review examines how childhood trauma influences psychological outcomes post-psychedelic use, urging for more inclusive, trauma-informed research.
Jul 30, 2026
NeuroscienceA global study finds high ventilation breathwork reduces experiential avoidance and enhances mental well-being through altered states of consciousness.
Jul 30, 2026
NeurosciencePhotorexant, a photoswitchable orexin antagonist, enables precise control of orexin signaling, aiding psychiatric disorder research.
Jul 30, 2026
Clinical TrialsPsychological distress may influence cancer immunotherapy outcomes, suggesting new biomarkers and therapeutic strategies.
Jul 30, 2026
NeuroscienceA recent study examines DMT's effects on consciousness, revealing complex brain dynamics but lacking a unified causal account. Further research is needed.
Jul 30, 2026
NeuroscienceA recent study investigates DMT's complex effects on consciousness, emphasizing its potential to reorganize perception and brain connectivity, while introducing new models for future research.
Jul 30, 2026
Clinical TrialsMB-PAT's group-based model in Canada offers a scalable approach to address cancer-related demoralization, leveraging mindfulness and psilocybin.
Jul 30, 2026
Clinical TrialsA scoping review of ketamine guidelines aims to standardize treatment for chronic non-cancer pain, enhancing safety and efficacy.
Jul 30, 2026
Clinical TrialsA case report reveals esketamine nasal spray's promise for ECT-refractory bipolar depression, highlighting the need for further research.
Jul 30, 2026
Clinical TrialsEsketamine shows promise as a rapid antidepressant for cancer-related depression, but further research is needed to confirm long-term safety and optimal dosing.
Jul 30, 2026
Clinical TrialsA pilot trial shows psilocybin-assisted therapy may reduce PTSD symptoms in veterans, suggesting a new treatment avenue pending further research.
Jul 30, 2026
PolicyThe EPA's proposed SNURs under TSCA could impact the production of chemicals used in psychedelics, requiring 90-day notifications.
Jul 30, 2026
Public HealthA new clinic in Charlotte provides ketamine therapy to veterans, marking a significant step in integrating psychedelics into mainstream healthcare.
Jul 29, 2026
Clinical TrialsA validated method for analyzing ketamine in hair may revolutionize drug monitoring, offering insights into long-term use and therapeutic applications.
Jul 29, 2026
Clinical TrialsInnovative ketamine analysis methods using hair samples improve drug monitoring accuracy in trials and forensic investigations.
Jul 29, 2026
Clinical TrialsCase studies from Jamaica suggest psilocybin therapy may aid psychological and somatic symptoms, yet small sample sizes limit conclusions.
Jul 29, 2026
NeuroscienceResearch highlights critical periods in youth as key for early intervention in mental health, offering insights for future psychedelic studies.
Jul 29, 2026
NeuroscienceRecent research suggests orexin antagonists may treat depression by modulating glucose-insulin homeostasis, offering new therapeutic avenues.
Jul 29, 2026
Clinical TrialsKetamine shows promise for rapid relief in treatment-resistant depression, but questions about long-term safety and optimal dosing remain.
Jul 29, 2026
Clinical TrialsA trial at Huzhou Maternity & Child Health Care Hospital finds esketamine improves postoperative sleep and reduces opioid use in laparoscopic surgery.
Jul 29, 2026
Clinical TrialsA trial shows ketamine's feasibility in treating suicidal adolescents in emergency settings, though efficacy over placebo remains unproven, suggesting further research.
Jul 29, 2026
Clinical TrialsKetamine infusions post-amputation may reduce pain and opioid use, impacting public health and pain management protocols.
Jul 29, 2026
PolicyThe FDA's reorganization could streamline psychedelic drug approvals, impacting research timelines and market entry.
Jul 29, 2026
PolicyThe DEA's proposed rule on suspicious orders of controlled substances could increase scrutiny and compliance costs for psychedelic companies.
Jul 29, 2026
NeuroscienceNew research highlights neuroimmune pathways as key to ketamine and psychedelics' rapid antidepressant effects, offering insights for future therapies.
Jul 28, 2026
Clinical TrialsEsketamine significantly reduces limb withdrawal in children receiving rocuronium, highlighting its potential in optimizing pediatric anesthesia protocols.
Jul 28, 2026
NeuroscienceRecent research identifies fungal metabolites as promising modulators for tauopathies, highlighting the role of computational drug discovery.
Jul 28, 2026
Clinical TrialsCurrent treatments for MDD with anxiety lack robust data. New trials with anxiety-specific endpoints are crucial for informed decisions.
Jul 28, 2026
NeuroscienceTargeting metabolic pathways in multiple sclerosis (MS) could shift treatment from broad immunosuppression to precise metabolic reprogramming, offering new therapeutic avenues.
Jul 28, 2026
NeuroscienceOntological tourism in psychedelic science highlights the tension between subjective experiences and scientific explanations, posing risks to research integrity.
Jul 28, 2026
NeurosciencePsilocybin microdosing induces beneficial epigenetic changes in rats, suggesting therapeutic potential for mood and anxiety disorders.
Jul 28, 2026
Clinical TrialsEEG and MEG show promise in psilocybin depression treatment, but larger trials are needed to validate predictive biomarkers.
Jul 28, 2026
NeuroscienceResearch identifies factors influencing psilocybin's behavioral effects in mice, aiding in the development of more effective therapeutic models.
Jul 28, 2026
Clinical TrialsVet students' attitudes towards psychedelics shape their expectations of psychedelic therapies, highlighting the role of education in emerging veterinary practices.
Jul 28, 2026
Clinical TrialsRecent research indicates that ketamine and esketamine do not significantly affect liver enzymes in treatment-resistant depression patients.
Jul 28, 2026
NeuroscienceRecent research highlights convergent neuroimmune pathways in ketamine and psychedelic antidepressant effects, focusing on IL-15 and MCP-1 as key regulatory hubs.
Jul 28, 2026
Clinical TrialsNew biomarkers for bipolar disorder may improve the precision of psychedelic treatments like ketamine, but further validation is needed.
Jul 28, 2026
Clinical TrialsNew study evaluates the hepatic safety of ketamine and esketamine in treating resistant depression, offering insights for clinical guidelines.
Jul 28, 2026
PolicyThe FDA's upcoming Pediatric Advisory Committee meeting could influence future regulatory approaches to pediatric psychedelic therapies.
Jul 28, 2026
NeuroscienceA novel model for SSRI treatment in OCD emphasizes individual response dynamics, challenging traditional mean-effect approaches.
Jul 27, 2026
Public HealthThis analysis explores the cardiovascular risks of sympathomimetic drugs, emphasizing individualized treatment and early intervention.
Jul 27, 2026
Clinical TrialsA scoping review of ketamine-assisted psychotherapy for depression underscores potential benefits but calls for more high-quality trials and detailed reporting.
Jul 27, 2026
Clinical TrialsClassic psychedelics may offer novel pathways for chronic pain management by targeting central nervous system maladaptation, though translational barriers remain.
Jul 27, 2026
Public HealthMedicine 4.0 emphasizes equitable access to healthcare and knowledge, challenging current frameworks in psychedelic research and treatment.
Jul 27, 2026
Clinical TrialsA review of psilocybin microdosing for depression reveals potential benefits but highlights significant methodological limitations, indicating insufficient evidence for widespread clinical use.
Jul 27, 2026
Clinical TrialsA review highlights the variability in integration practices in psychedelic therapy, urging standardized protocols for improved safety and trial efficacy.
Jul 26, 2026
NeuroscienceA study supports the Entropic Brain Hypothesis, showing that different consciousness states, including those induced by psychedelics, vary in brain activity entropy.
Jul 26, 2026
NeuroscienceEEG spectral power effectively decodes subanaesthetic ketamine states, while phase connectivity lacks cross-subject transferability, impacting research methods.
Jul 26, 2026
Clinical TrialsA systematic review examines ketamine's potential for treating depression in BPD, highlighting the need for more targeted research.
Jul 26, 2026
Clinical TrialsPreclinical research on Glycyrrhiza glabra root decoction highlights canrenoic acid's potential in anxiety treatment, urging further clinical trials.
Jul 25, 2026
NeuroscienceElunetirom, a TRβ prodrug, enhances neuroplasticity and mitochondrial function, suggesting a novel treatment path for depression.
Jul 25, 2026
Clinical TrialsA comprehensive review of psychedelic clinical trial design offers insights for optimizing methodologies, potentially enhancing study credibility.
Jul 25, 2026
NeuroscienceChlorogenic acid shows partial, sex-dependent effects on ketamine-induced schizophrenia-like symptoms in rats, suggesting potential dietary interventions.
Jul 24, 2026
NeuroscienceA study reveals ECT's impact on specific brain networks, offering insights into its antidepressant efficacy and potential therapeutic refinements.
Jul 24, 2026
NeuroscienceA new evolutionary theory suggests nightmares may serve adaptive functions, informing potential clinical interventions.
Jul 24, 2026
NeurosciencePhytochemicals show promise as NMDAR inhibitors, offering potential therapeutic avenues for neurodegenerative diseases by mitigating excitotoxicity.
Jul 24, 2026
NeuroscienceA study on DOI shows decreased cortical network modularity in mice, highlighting the role of thalamo-cortical interactions in psychedelic effects.
Jul 24, 2026
NeuroscienceThis analysis examines the effects of GluN2D modulators and ketamine on GABA, LTP, and motivation, offering insights for psychiatric therapies.
Jul 24, 2026
Clinical TrialsA new study investigates loneliness in depression treatment, offering insights that could influence future psychedelic therapy research.
Jul 24, 2026
NeuroscienceiPSC-derived neuron study reveals shared effects of rapid-acting antidepressants, offering insights into treatment-resistant depression mechanisms.
Jul 24, 2026
Clinical TrialsA recent study shows DDS and NAC have synergistic effects in reducing pain after spinal cord injury, highlighting oxidative stress modulation.
Jul 23, 2026
Clinical TrialsA recent study highlights the risk of sexual dysfunction when SSRIs are combined with brexpiprazole, emphasizing the need for further research.
Jul 23, 2026
Clinical TrialsA pilot study suggests personalized DBS may improve symptoms in treatment-resistant schizophrenia, offering a new therapeutic avenue.
Jul 23, 2026
Clinical TrialsA recent study indicates low-dose psilocybin has a favorable cardiac safety margin, supporting its potential as a treatment for mood disorders with minimal valvular heart disease risk.
Jul 23, 2026
Clinical TrialsEsketamine offers dual benefits in bariatric surgery by reducing pain and improving mental health, presenting a safer alternative to opioids.
Jul 23, 2026
Clinical TrialsAn exploratory study suggests psilocybin and MDMA do not harm working memory, but further research is needed to confirm findings.
Jul 23, 2026
PolicyThe DEA's extension of Form 222 maintains regulatory oversight of Schedules I and II substances, impacting psychedelic research and industry compliance.
Jul 23, 2026
PolicyEPA's proposed SNURs under TSCA may affect the manufacturing and processing of chemicals relevant to psychedelic research, requiring 90-day pre-notification.
Jul 23, 2026
PolicyThe FDA's strategy on CMC readiness could streamline psychedelic therapy development, addressing unmet medical needs faster.
Jul 23, 2026
Public HealthA mushroom species producing amatoxins and psilocybin poses risks for therapeutic use, necessitating strict identification and regulation.
Jul 22, 2026
Clinical TrialsA study warns against systemic TMEM16A inhibition in stroke therapy, highlighting the need for targeted modulation of cerebral perfusion.
Jul 22, 2026
Public HealthResearch shows MSM sex workers and content creators have different chemsex patterns, necessitating specific harm reduction approaches.
Jul 22, 2026
PolicyTrump's executive order could streamline regulatory processes and expand access to psychedelic therapies, impacting research and healthcare integration.
Jul 22, 2026
NeuroscienceGalerina indica's dual production of psilocybin and amatoxins offers insights into fungal evolution but poses safety risks.
Jul 22, 2026
NeuroscienceKetamine remains in neuronal compartments after systemic clearance, suggesting potential long-term effects on brain function and therapeutic applications.
Jul 22, 2026
NeuroscienceA computational study highlights BeC19's potential for DMT detection, suggesting new paths for sensor development in clinical and forensic fields.
Jul 22, 2026
Public HealthA recent study links ketamine abuse to sexual health issues, highlighting the need for updated clinical guidelines and public health messaging.
Jul 22, 2026
Clinical TrialsA historical review of psycholytic therapy offers insights into early psychedelic-assisted psychotherapy, emphasizing the role of psychedelics as facilitators.
Jul 22, 2026
NeuroscienceA study reveals VR's potential in enhancing transformative experiences, suggesting applications in mental health and personal development.
Jul 22, 2026
Clinical TrialsThis analysis explores recent advancements in treatment-resistant depression research, focusing on staging, measurement-based care, and demographic-specific interventions.
Jul 22, 2026
Clinical TrialsMagnesium-ibogaine shows promise in treating PTSD and TBI in veterans, with mystical experiences and DMN changes as key mechanisms.
Jul 22, 2026
Clinical TrialsPacific Mind Health's ketamine therapy targets grief-related depression, signaling a shift in psychedelic-assisted treatments.
Jul 22, 2026
PolicyThe FDA's regulation of psychedelics will shape research, patient care, and market dynamics. Understanding this framework is crucial.
Jul 22, 2026
NeuroscienceResearch shows social hierarchy affects stress and ketamine response in mice, suggesting personalized approaches for psychiatric disorders.
Jul 21, 2026
NeuroscienceResearchers have developed a bacterial pathway to produce DMT, potentially transforming its scalability for research and pharmaceutical applications.
Jul 21, 2026
NeuroscienceS-ketamine and S-HNK target neuroinflammation via TLR4/PPARα signaling, offering new insights into depression treatment.
Jul 21, 2026
NeuroscienceA recent study finds social hierarchy influences ketamine's effects on stress in mice, hinting at personalized treatment potential.
Jul 21, 2026
Clinical TrialsA review of psilocybin's potential as a therapy for epilepsy highlights the need for more clinical trials to assess efficacy and safety.
Jul 21, 2026
Clinical TrialsPsilocybin modulates decision-making by enhancing learning from positive outcomes and reducing negative outcome impact, aiding psychiatric applications.
Jul 21, 2026
NeuroscienceA theoretical framework suggests multi-scale interventions for complex diseases like cancer and depression, impacting future research.
Jul 21, 2026
Clinical TrialsRecent studies indicate promising outcomes for psychedelics in treating substance use disorders, urging further research and integration into treatment protocols.
Jul 21, 2026
Clinical TrialsEli Lilly's $2.8 billion investment in psychedelic research may redefine clinical trial methodologies and expand treatment options.
Jul 21, 2026
Clinical TrialsA systematic review of (Es)ketamine for functional neurological disorder highlights potential benefits but stresses the need for controlled trials.
Jul 20, 2026
Clinical TrialsA preprint study examines esketamine's effects on anhedonia, suggesting potential beyond depression treatment. Peer review is pending.
Jul 20, 2026
Clinical TrialsBlood-based neurofilament light chain shows promise as a biomarker in neurodegenerative trials, but variability in outcomes necessitates further validation.
Jul 20, 2026
NeuroscienceKetamine's analgesic and dissociative effects are mediated by distinct neural mechanisms, suggesting potential for targeted therapies.
Jul 20, 2026
NeurosciencePsilocybin affects dendritic signaling via serotonin receptors, crucial for understanding its therapeutic potential.
Jul 20, 2026
Clinical TrialsA case report suggests ibogaine may aid in treating ketamine use disorder, showing sustained abstinence and improved mental health in a patient.
Jul 20, 2026
MarketEli Lilly's $3.8 billion investment in psychedelic medicine signifies Big Pharma's growing interest, potentially accelerating research and market legitimacy.
Jul 20, 2026
NeuroscienceA novel framework suggests treatment-resistant depression results from multi-pillar neurological failures, challenging single-target antidepressant approaches.
Jul 20, 2026
NeuroscienceA novel approach suggests treatment-resistant depression stems from multi-pillar neural failures, not single neurotransmitter issues.
Jul 20, 2026
Public HealthA study examines MDMA, methylamphetamine, and THC trends in Victoria, Australia drivers, informing public health and safety policies.
Jul 20, 2026
NeuroscienceKetamine's antidepressant effects are linked to CX3CL1/CX3CR1 signaling, offering insights into new therapeutic targets for depression.
Jul 20, 2026
Clinical TrialsThis analysis examines a hybrid group therapy model for psilocybin-assisted therapy, highlighting its potential for scalable public health interventions.
Jul 20, 2026
NeuroscienceRecent research identifies distinct neural pathways for ketamine's analgesic and dissociative effects, suggesting potential for targeted therapies.
Jul 20, 2026
NeuroscienceA novel theoretical model proposes a nested-boundary framework for understanding psychological states, offering insights into psychedelic risk profiles.
Jul 19, 2026
MarketThe psychedelic drug market's recent buy signal indicates increased investor interest, potentially boosting funding for mental health treatment development.
Jul 19, 2026
NeuroscienceA study finds a temporary drop in EEG complexity at DMT session onset, urging researchers to exclude initial data to avoid non-stationary effects.
Jul 19, 2026
NeuroscienceA study reports a temporary EEG complexity dip at DMT session onset, highlighting procedural causes and urging data exclusion for accuracy.
Jul 19, 2026
Clinical TrialsResearch highlights the variability in psilocybin content at retreats and the potential of rapid assays for dose standardization, impacting safety protocols.
Jul 18, 2026
Clinical TrialsThe DMT Abort Tracker aids cluster headache research by collecting detailed data on dosing, efficacy, and safety, influencing future trials.
Jul 18, 2026
NeurosciencePsilocybin shows sex-specific effects on sensorimotor gating in a schizophrenia mouse model, highlighting potential therapeutic insights.
Jul 18, 2026
Clinical TrialsThe DMT Abort Tracker captures detailed data on its use for cluster headaches, aiding research and trial design.
Jul 18, 2026
NeuroscienceA comprehensive review of PTSD's neurobiological mechanisms highlights the need for evidence-based, trauma-informed clinical practices.
Jul 17, 2026
NeuroscienceNigerian medicinal plants show promise in drug discovery, especially for psychotropic uses, but face research and development challenges.
Jul 17, 2026
NeuroscienceThe intersection of psychedelic research and mysticism raises concerns about biases that may affect scientific rigor and future research directions.
Jul 17, 2026
Clinical TrialsIntegrated trauma-focused treatments for adolescents with PTSD and SUD show promise, notably RRFT, but require larger trials for validation.
Jul 17, 2026
NeuroscienceA study reveals robust visuomotor mismatch EEG responses in humans, potentially simplifying clinical EEG setups and advancing translational research.
Jul 17, 2026
NeuroscienceNew research shows humans exhibit visuomotor mismatch responses, akin to mice, using wireless EEG and VR, enhancing sensory processing studies.
Jul 17, 2026
Clinical TrialsCombination therapies in Parkinson's research may offer new pathways for disease modification, addressing the complexity that hinders current treatments.
Jul 17, 2026
Clinical TrialsA study reveals oral esketamine's limited effect on BDNF levels in treatment-resistant depression, influencing future research and treatment strategies.
Jul 17, 2026
Clinical TrialsA meta-analysis suggests ketamine may aid short-term abstinence in SUD, though long-term efficacy and safety are unclear.
Jul 17, 2026
Evergreen guides, US and state policy orientation, and daily signal on science and regulation — The Psychedelic Journal as one journal voice.
Global psychedelic research, law, and access (pillar guide)
US and state law, scheduling, and policy hub (not legal advice)
Guides — plain-English primers on each psychedelic therapy
Tools — quizzes, provider lookups, legal-status checkers
Policy calendar: comment windows and milestones we track on-page
Data hub: calendars, tools, and structured research datasets
Glossary A–Z across compounds, law, and policy terms
Sources & method: what we ingest, how we score it, and limits
Curated reading paths for onboarding and deeper study
Start here: how to use this journal and where to go next
Get the daily briefing in your inbox
Law, clinical science, and policy signal on psychedelic research — on our publish cadence. Start at the The Psychedelic Journal homepage.
Subscribe freeSuggest a tool, topic, or improvement that would make this site more useful.